Attention Deficit/ Hyperactivity Disorder. Disturbance of activity and attentionAttention deficit:disorder with hyperactivityhyperactivity disordersyndrome with hyperactivityExcl.:hyperkinetic disorder associated with conduct disorder (F90.1)
Conditions
Interventions
Intervention group: Patients with Attention Deficit Hyperactivity Disorder receive long-acting methylphenidate 18 mg tablets, manufactured by Sandoz, at a dose of 0.6-1.2 mg / kg, orally, once daily f
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
7 Years to 9 Years
Inclusion criteria
Inclusion criteria: Age between 7 and 9 years old - - - Diagnostic and Statistical Manual-4 criteria for diagnosis of attention-deficit hyperactivity disorder Parental consent to participate in research Lack of history of medication for the disorder
Exclusion criteria
Exclusion criteria: Wechsler's IQ of less than 91 based on Wechsler's test - - other major psychiatric illnesses including ASD any physical defects that prevent tests, including severe visual and hearing impairment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Score in the Hutchin's Theory of Mind Questionnaire. Timepoint: At baseline and one month after treatment with long-acting methylphenidate. Method of measurement: Hutchin`s Theory of Mind Questionnaire.;Score in the TOM(Theory of Mind) test. Timepoint: At baseline and one month after treatment with long-acting methylphenidate. Method of measurement: TOM(Theory of Mind) test.;Score in Attention Deficit Hyperactivity Disorder Rating scale. Timepoint: At baseline and one month after treatment with long-acting methylphenidate. Method of measurement: Attention Deficit Hyperactivity Disorder Rating scale. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactRozita Davari Ashtiani
Shahid Beheshti University of Medical Sciences
Outcome results
None listed